Recent Investment Analysts’ Ratings Changes for Tempus AI (TEM)

A number of research firms have changed their ratings and price targets for Tempus AI (NASDAQ: TEM):

• 7/20/2026 – Tempus AI was downgraded by Lake Street Capital to “hold”.
• 7/20/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
• 7/16/2026 – Tempus AI had its price target raised by Guggenheim from $60.00 to $65.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Tempus AI had its “buy” rating reaffirmed by TD Cowen.
• 7/4/2026 – Tempus AI was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/30/2026 – Tempus AI was upgraded by Freedom Capital to “hold”.
• 6/17/2026 – Tempus AI had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 6/6/2026 – Tempus AI was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/2/2026 – Tempus AI is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 6/1/2026 – Tempus AI had its “buy” rating reaffirmed by BTIG Research. They now have a $80.00 price target on the stock.
• 6/1/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.

Insider Activity

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $46.70, for a total transaction of $7,763,875.00. Following the completion of the transaction, the chief executive officer directly owned 8,808,533 shares of the company’s stock, valued at $411,358,491.10. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 33,284 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total transaction of $1,910,168.76. Following the completion of the sale, the chief executive officer owned 167,763 shares of the company’s stock, valued at approximately $9,627,918.57. The trade was a 16.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 616,043 shares of company stock valued at $31,748,593. 24.26% of the stock is owned by insiders.

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.